IGF2BP1 is overexpressed in non‐small cell lung cancer (NSCLC) and associated with poor prognosis (in lung adenocarcinoma) at earlier onset: more than 3‐fold increased IGF2BP1 expression can be detected in 70% of NSCLCs where it positively correlates with a 30% reduction in tumour‐specific 5‐years survival after surgery (Kato et al., 2007; Shi et al., 2017). This evidence concerns the gene IGF2BP1 and lung adenocarcinoma.